IQVIA Holdings Inc. (NYSE:IQV) Position Boosted by OMERS ADMINISTRATION Corp

OMERS ADMINISTRATION Corp lifted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 20.2% during the 4th quarter, HoldingsChannel.com reports. The firm owned 7,595 shares of the medical research company’s stock after buying an additional 1,276 shares during the quarter. OMERS ADMINISTRATION Corp’s holdings in IQVIA were worth $1,492,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. JPMorgan Chase & Co. lifted its holdings in IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after acquiring an additional 583,396 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in IQVIA by 1.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company’s stock worth $1,068,000 after acquiring an additional 56 shares during the last quarter. Pallas Capital Advisors LLC bought a new position in IQVIA in the fourth quarter worth about $298,000. Fifth Third Wealth Advisors LLC lifted its holdings in IQVIA by 26.1% in the fourth quarter. Fifth Third Wealth Advisors LLC now owns 1,839 shares of the medical research company’s stock worth $361,000 after acquiring an additional 381 shares during the last quarter. Finally, Sendero Wealth Management LLC lifted its holdings in IQVIA by 25.4% in the fourth quarter. Sendero Wealth Management LLC now owns 45,221 shares of the medical research company’s stock worth $8,886,000 after acquiring an additional 9,153 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Trading Down 0.9%

IQVIA stock opened at $140.51 on Friday. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The firm has a market cap of $24.31 billion, a price-to-earnings ratio of 18.73, a price-to-earnings-growth ratio of 1.99 and a beta of 1.34. IQVIA Holdings Inc. has a 1 year low of $135.97 and a 1 year high of $252.88. The firm’s 50 day moving average price is $160.66 and its two-hundred day moving average price is $186.58.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.63 by $0.07. The firm had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The firm’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.54 earnings per share. On average, research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on IQV. UBS Group cut their target price on shares of IQVIA from $255.00 to $185.00 and set a “buy” rating on the stock in a report on Wednesday, May 7th. Robert W. Baird cut their target price on shares of IQVIA from $195.00 to $161.00 and set a “neutral” rating on the stock in a report on Wednesday, May 7th. Citigroup cut their target price on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Hsbc Global Res cut IQVIA from a “strong-buy” rating to a “hold” rating in a report on Friday, April 25th. Finally, BTIG Research cut IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. Eight analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and a consensus price target of $230.76.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.